# Research-context dose ranges for KLOW components — Legal KLOW

> Published research-context dose ranges for GHK-Cu, BPC-157, TB-500, and KPV. Information for research reading only — not dosing advice, not for human use.

What the published literature reports — not a prescription, not a protocol, not a recommendation.

## Research doses, not a protocol

No validated human dose exists for the KLOW blend, and none is given here. The 80 mg research vial (GHK-Cu 50 mg / BPC-157 10 mg / TB-500 10 mg / KPV 10 mg) is a vendor convention, not a tested or standardized formulation. Component dose ranges in the published literature span species and routes: BPC-157 was studied at 10 micrograms or 10 nanograms per kilogram intraperitoneal in rats; thymosin beta-4 stimulated keratinocyte migration at 10 picograms; GHK-Cu was investigated at nanomolar concentrations in cell culture and 0.1–3 mg/mL topically; KPV was effective at 10 nM in vitro and 100 micromolar in mouse drinking water. A pharmacokinetic mismatch is built into the vial — the tripeptides KPV and GHK-Cu clear far faster than BPC-157 (formal elimination half-life under 30 minutes), so a single co-formulated dose cannot hold all four components at matched exposures simultaneously. This page records what the literature reports, not a protocol or recommendation.

## Framing — what this page is and is not

This page summarizes the doses that have appeared in published research on each of the four KLOW components. The values are reported as the original investigators used them, in the species and by the routes they studied. No dose on this page is a recommendation. No combination dose for the KLOW blend appears in the published literature because no controlled trial of the blend has been published [05][08]. Material sold as 'research use only' is not pharmaceutical-grade and is not lawful for human or veterinary compounding in the United States.

## GHK-Cu — concentration and route ranges

GHK-Cu has been studied predominantly in cell culture and in topical formulations. The Pickart and Margolina 2018 microarray work used a 1 nM concentration on cultured human fibroblasts [01]. Topical cosmetic-research formulations are typically reported at 0.1–3 mg/mL [02]. The Jiang and colleagues 2023 collagen IV experiments used a 1:9 GHK-Cu to low-molecular-weight hyaluronic acid mass ratio in cultured fibroblasts and ex-vivo skin explants [03]. Plasma half-life is reported on the order of minutes, which is the pharmacokinetic reason GHK-Cu is typically studied topically rather than systemically. The injectable form of GHK-Cu was placed in FDA Category 2 in September 2023; topical GHK-Cu remained in Category 1 with restrictions in the same update [05][12].

## BPC-157 — predominantly 10 μg/kg in rats

The dominant rodent dose in the BPC-157 literature is 10 μg/kg, with several studies also reporting 10 ng/kg as a comparison dose. The 2003 Achilles tendon study used 10 μg/kg or 10 ng/kg intraperitoneal in Sprague-Dawley rats [04]. The 2010 angiogenesis study used 10 μg/kg intraperitoneal in rats [05]. The colocutaneous fistula study used 10 μg/kg or 10 ng/kg intraperitoneal or intragastric [16]. Reported rat plasma half-life is roughly 4 hours. BPC-157 is reported as stable in human gastric juice for at least 24 hours, which is one of the published rationales for oral administration in research settings. The 2024 interstitial cystitis pilot used intravesical injection — a route not previously studied in animal models at scale [07].

## TB-500 — 1–10 mg/kg in rodents

TB-500 in rodent wound-healing research has been reported in the 1–10 mg/kg range, considerably higher on a mass basis than BPC-157 in part because the molecule itself is larger (4,963 Da versus 1,420 Da). Full-length Thymosin Beta-4 in the ophthalmic Phase 3 program (RGN-259) is administered as a 0.1% topical ophthalmic solution [14]. The fragment sold as TB-500 is not pharmacokinetically equivalent to the full-length molecule; published PK data on the fragment is sparse. Full-length Tβ4 has a reported plasma half-life of about 2 hours in humans [13].

## KPV — nanomolar in vitro, microgram doses in mouse models

KPV has been studied at nanomolar to micromolar concentrations in cell culture and at microgram doses in mouse models. The Dalmasso 2008 work reported a PepT1 Km of approximately 160 μmol/L for KPV uptake in Caco2-BBE and THP-1 cells, and used oral KPV in DSS and TNBS murine colitis [09]. The Manna and Aggarwal 2006 NF-κB inhibition work used micromolar peptide concentrations in cell-based reporter assays [10]. KPV is rapidly degraded by intestinal peptidases but retains activity via PepT1-mediated cellular uptake, which is the rationale for oral administration in colitis research.

## Routes studied in the published literature

Across the four components, the published research-administration routes include: intraperitoneal (BPC-157, TB-500 in rodent studies), intragastric/oral (BPC-157, KPV), topical (GHK-Cu in skin research, Tβ4 in corneal research), intravenous (Tβ4 in cardiac repair studies), and intravesical injection (BPC-157, in the 2024 interstitial cystitis pilot only). Subcutaneous is a vendor convention for research administration of the blend but does not correspond to any specific published efficacy study of the four together [07][14].

## Stability of the four together in solution

Stability data for the four peptides reconstituted together is vendor-claimed rather than peer-reviewed. The components themselves have different stability profiles: BPC-157 is reported as stable in human gastric juice for at least 24 hours, GHK-Cu is rapidly cleared from plasma with reported half-lives on the order of minutes, full-length Thymosin Beta-4 has a reported plasma half-life of about 2 hours in humans (data on the TB-500 fragment is sparse), and KPV is rapidly degraded by intestinal peptidases but retains activity via PepT1-mediated cellular uptake [09][13]. None of those single-component stability values predicts how the four behave in a shared diluent over the storage and use period of a research vial. Peptide-peptide interaction, ratio accuracy at the time of compounding, and degradation kinetics across multiple freeze-thaw cycles are not characterized in any published source.

## Why no combination dose appears here

The KLOW blend itself has not been the subject of any published controlled trial — no animal model, no human study, no pharmacokinetic characterization of the four peptides together. The 50/10/10/10 mg ratio that appears on commercial vials is a vendor convention, not a tested formulation [08]. The four peptides have different molecular weights, different plasma half-lives, different routes of administration in their own published literatures, and different regulatory standings. Combining them does not produce a single drug — it produces a mixture whose pharmacology has not been characterized. Any dose extrapolated from a single-component animal study to the blend introduces a second extrapolation on top of the species-to-species step the original investigators already made. This site does not perform that extrapolation.

---

A source-linked reading room for the public regulatory record on KLOW — not a clinic, not a law firm, not a vendor.